These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36198244)

  • 1. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
    Basse C; Chabanol H; Bonte PE; Fromantin I; Girard N
    Lung Cancer; 2022 Nov; 173():116-123. PubMed ID: 36198244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].
    Wang J; Chi Y; Chen H; Jia B; Zhai X; Ma M; Li J; Zhuo M
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):493-500. PubMed ID: 35899447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
    J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
    Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
    Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
    [No Abstract]   [Full Text] [Related]  

  • 5. The development of amivantamab for the treatment of non-small cell lung cancer.
    Brazel D; Nagasaka M
    Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
    Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
    Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
    Okahisa M; Udagawa H; Matsumoto S; Kato T; Yokouchi H; Furuya N; Kanemaru R; Toyozawa R; Nishiyama A; Ohashi K; Miyamoto S; Nishino K; Nakamura A; Iwama E; Niho S; Oi H; Sakai T; Shibata Y; Izumi H; Sugiyama E; Nosaki K; Umemura S; Zenke Y; Yoh K; Kah Mun Low G; Zhuo J; Goto K
    Lung Cancer; 2024 May; 191():107798. PubMed ID: 38669727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
    Singh-Kandah S; Wang K; Xia K; Lain Johnson A; D'Andrea DM; Shu CA; Bray Dougherty L; Gallitano SM
    Clin J Oncol Nurs; 2024 Sep; 28(5):1-8. PubMed ID: 39324708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
    Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
    Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
    Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
    Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
    Russell MC; Garelli AM; Reeves DJ
    Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amivantamab for the treatment of
    Vyse S; Huang PH
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.
    Califano R; Tariq N; Compton S; Fitzgerald DA; Harwood CA; Lal R; Lester J; McPhelim J; Mulatero C; Subramanian S; Thomas A; Thatcher N; Nicolson M
    Drugs; 2015 Aug; 75(12):1335-48. PubMed ID: 26187773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Chon K; Larkins E; Chatterjee S; Mishra-Kalyani PS; Aungst S; Wearne E; Subramaniam S; Li Y; Liu J; Sun J; Charlab R; Zhao H; Saritas-Yildirim B; Bikkavilli RK; Ghosh S; Philip R; Beaver JA; Singh H
    Clin Cancer Res; 2023 Sep; 29(17):3262-3266. PubMed ID: 37022784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
    Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
    J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
    Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
    Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
    Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
    J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.
    Lee JS; Woo J; Kim TM; Kim N; Keam B; Jo SJ
    Acta Derm Venereol; 2024 Aug; 104():adv40555. PubMed ID: 39192813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.